ESTRO38 Congress Report

oblique needles. Further developments, especially in the field of custom3D printed applicators can adopt the findings to optimize the implant geometry and dose distribution to further improve the therapeutic ratio of brachytherapy.

OVOIDS IC

RING IC

OVOIDS IC/IS

RING IC/IS

No. of Patients

119

161

180

489

Patient Age

52 (14)

51 (16)

49 (14)

51(13)

FIGO Stage (I / II / III+IV) BT1 Tumour Width (cm)

27%/55%/18% 30% 60%/10% 35%/54%/11% 9%/63%/28%

4.3 (1.2)

3.9 (0.9)

4.1 (1.1)

4.5 (9.2)

CTVHR Vol. (cm3)

31.9 (16.5) 85.5 (7.4) 88.5 (23.6) 89% / 11% 74.5 (17.4)

28.9 (18.0) 91.2 (10.0) 66.9 (18.7) 86% / 14% 65.4 (14.0)

32.6 (15.9) 88.6 (5.9) 78.3 (22.0) 38% / 62% 69.5 (14.8)

35.6 (18.9) 91.2 (5.1) 73.5 (23.8) 35% / 65% 67.5 (12.7)

CTVHR D90% (Gy EQD210)

V85 Gy EQD210 (cm3)

No. of patients with IC vs IC/IS (%) Bladder ICRU Point (Gy EQD23)

Bladder D2cm3 (Gy EQD23) 82.9 (10.0)

75.4 (9.2) 68.7 (7.1)

79.4 (9.4) 63.1 (7.6)

75.1 (9.4) 69.6 (10.1)

Rectovaginal Ref. Point (Gy EQD23) Rectum D2cm3 (Gy EQD23) 66.3 (7.2) Vagina 5mm lateral (Gy EQD23)

64.8 (7.0)

63.0 (6.6) 87.5 (12.7)

62.7 (7.4)

61.8 (6.3) 87.0 (12.3)

104.6 (23.1)

109.5 (29.3)

Table 1. Patient characteristics, target and OAR doses for each centre group. Mean values and standard deviations (1 SD) are displayed.

Congress report | BRACHYTHERAPY

31